Tyra Biosciences doses first child in Phase 2 achondroplasia study of dabogratinib

Tyra Biosciences, Inc.

First child dosed in BEACH301 Phase 2 study of dabogratinib (formerly TYRA-300) for achondroplasia.
Initial results from safety sentinel cohort expected in second half of 2026.
Dabogratinib is an FGFR3 inhibitor, Tyra's lead candidate for achondroplasia.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.